About Manus Bio
Manus Bio is a company based in Cambridge (United States) founded in 2011 by Gregory Stephanopoulos and Ajikumar Parayil. Manus Bio has raised $115.93 million across 17 funding rounds from investors including Gates Foundation, BBGI and SBIR. Manus Bio offers products and services including Scale-up Platform, BioStevia, Nootkatone, and Valencene. Manus Bio operates in a competitive market with competitors including Evonik, Kallyope, Proklean Technologies, Calyxia and Mint Innovation, among others.
- Headquarter Cambridge, United States
- Founders Gregory Stephanopoulos, Ajikumar Parayil
-
Sectors
Chemicals & MaterialsHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Manus Bio Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$115.93 M (USD)
in 17 rounds
-
Latest Funding Round
$21.23 M (USD), Series B
May 31, 2023
-
Investors
Gates Foundation
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Manus Bio
Manus Bio offers a comprehensive portfolio of products and services, including Scale-up Platform, BioStevia, Nootkatone, and Valencene.
Platform for engineering and scaling bioalternatives sustainably.
Sustainable stevia alternative for better-tasting natural sweeteners.
Flavor compound produced via biomanufacturing for cost-effective use.
Sustainable flavor ingredient derived from microbial cell factories.
People of Manus Bio
Unlock access to complete
Funding Insights of Manus Bio
Manus Bio has successfully raised a total of $115.93M across 17 strategic funding rounds. The most recent funding activity was a Series B round of $21.23 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Manus Bio
Manus Bio has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, BBGI and SBIR.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Seed & early stage tech-focused VC investment company funding companies in the US
|
Locked | Locked | Locked | |
|
Venture capital fund backed by the US Government
|
Locked | Locked | Locked | |
|
Charitable foundation investments on poverty reduction and healthcare
|
Locked | Locked | Locked |
Investor details for Manus Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Manus Bio
Investment portfolio details for Manus Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Manus Bio
Detailed financials for Manus Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Manus Bio Comparisons
Peer comparison for Manus Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Manus Bio
Manus Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Evonik, Kallyope, Proklean Technologies, Calyxia and Mint Innovation, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Green specialty chemicals are developed and supplied for multiple industries.
|
|
| Locked | Locked | Locked |
The gut-brain axis is explored for therapeutic and nutritional innovations.
|
|
| Locked | Locked | Locked |
Probiotic-based cleaning agents are manufactured for industrial use.
|
|
| Locked | Locked | Locked |
Green chemicals are developed using microcapsule technology for sustainability.
|
|
| Locked | Locked | Locked |
Provider of clean technology for critical metal recovery from e-waste
|
Detailed competitors of Manus Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Manus Bio
Complete news archive for Manus Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Manus Bio
Manus Bio was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Manus Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ajikumar Parayil is the current CEO of Manus Bio. They have also founded this company.
Manus Bio is a funded company, having raised a total of $115.93M across 17 funding rounds to date.
Manus Bio was founded in 2011 in Cambridge, United States, within the biotechnology sector. Phytochemicals are produced through microbial fermentation, where natural processes are recreated in microorganisms. Carbon and plant-derived substrates are converted into ingredients for flavors, fragrances, food, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Operations focus on sustainable products derived from natural resources.
Manus Bio's top competitors include Kallyope, Mint Innovation and Calyxia.
Manus Bio offers Scale-up Platform, BioStevia, Nootkatone, and Valencene.
Manus Bio has 6 investors. Key investors include Gates Foundation, BBGI, SBIR, National Science Foundation, and Nelstone Ventures.